PMS-SALBUTAMOL SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

SALBUTAMOL (SALBUTAMOL SULFATE)

から入手可能:

PHARMASCIENCE INC

ATCコード:

R03AC02

INN（国際名）:

SALBUTAMOL

投薬量:

2MG

医薬品形態:

SOLUTION

構図:

SALBUTAMOL (SALBUTAMOL SULFATE) 2MG

投与経路:

INHALATION

パッケージ内のユニット:

2.5ML

処方タイプ:

Prescription

治療領域:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

製品概要:

Active ingredient group (AIG) number: 0108887001; AHFS:

認証ステータス:

APPROVED

承認日:

2010-05-04

製品の特徴

PRODUCT MONOGRAPH
PR
PMS-SALBUTAMOL
Salbutamol Sulphate Inhalation Solution, BP
0.05%; 0.1%; 0.2%
0.5 mg/mL; 1 mg/mL; 2 mg/mL
BRONCHODILATOR
Beta
2
-adrenergic stimulant
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
Date of Revision:
August 10, 2018
www.pharmascience.com
Submission Control No: 217525
_ _
_pms-SALBUTAMOL Product Monograph Page 2 of 24_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
....................................................................................................
8
DOSAGE AND ADMINISTRATION
................................................................................
9
OVERDOSAGE
................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 11
STORAGE AND STABILITY
.........................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 13
PART II: SCIENTIFIC INFORMATION
...............................................................................
14
PHARMACEUTICAL INFORMATION
.........................................................................
14
CLINICAL TRIALS
...........................................................................................